Practical Considerations for Molecular Pathologists: Navigating Tissue-Informed MRD Testing with Signatera

Molecular residual disease (MRD) testing is transforming oncology by enabling treatment monitoring and early recurrence detection. This corporate workshop focuses on the molecular pathologist’s critical role in the successful send-out and implementation of tissue-informed MRD testing with Signatera. We’ll cover essential pre-analytical and analytical factors, including tumor tissue selection, sample quality requirements, and pathology coordination. Real-world challenges—such as tissue adequacy, FFPE block logistics, and clinical workflow integration—will be addressed. Case-based discussions will illustrate best practices for preserving sample integrity and maximizing clinical utility. This workshop is designed for both molecular and non-molecular pathologists and will offer practical insights for embedding MRD testing into routine operations amid the era of personalized oncology.